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Abstract
Background: The gut microbiome is increasingly recognized as a contributor to disease states. Patients with type 1
diabetes (DM1) have distinct gut microbiota in comparison to non-diabetic individuals, and it has been linked to
changes in intestinal permeability, inflammation and insulin resistance. Prebiotics are non-digestible carbohydrates
that alter gut microbiota and could potentially improve glycemic control in children with DM1. This pilot study
aims to determine the feasibility of a 12-week dietary intervention with prebiotics in children with DM1.
Methods/design: This pilot study is a single-centre, randomized, double-blind, placebo-controlled trial in children
aged 8 to 17 years with DM1 for at least one year. Participants will be randomized to receive either placebo (maltodextrin
3.3 g orally/day) or prebiotics (oligofructose-enriched inulin 8 g orally/day; Synergy1, Beneo, Mannheim, Germany).
Measures to be assessed at baseline, 3 months and 6 months include: anthropometric measures, insulin doses/regimens,
frequency of diabetic ketoacidosis, frequency of severe hypoglycemia, average number of episodes of hypoglycemia per
week, serum C-peptide, HbA1c, serum inflammatory markers (IL-6, IFN-gamma, TNF-alpha, and IL-10), GLP-1 and GLP-2,
intestinal permeability using urine assessment after ingestion of lactulose, mannitol and 3-O-methylglucose, and stool
sample collection for gut microbiota profiling.
Discussion: This is a novel pilot study designed to test feasibility for a fully powered study. We hypothesize
that consumption of prebiotics will alter gut microbiota and intestinal permeability, leading to improved
glycemic control. Prebiotics are a potentially novel, inexpensive, low-risk treatment addition for DM1 that
may improve glycemic control by changes in gut microbiota, gut permeability and inflammation.
Trial registration: ClinicalTrials.gov: NCT02442544. Registered on 10 March 2015.
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Background
The gut microbiome plays a key role in health but is
increasingly recognized as a contributor to various
disease states when an imbalance or dysbiosis occurs.
Both animal and human studies found a difference in
microbial composition between those that develop
type 1 diabetes from those that did not develop dia-
betes [1]. In animal studies, interventions that change
the gut microbiota can alter immune response and
can play a role in the development of type 1 diabetes
[2]. In children with type 1 diabetes (DM1), alter-
ations in gut microbiota have been identified [3–6].
For example, bifidobacteria have previously been
found to negatively correlate with beta-cell auto-
immunity in Finnish children with diabetes-related auto-
antibodies [3] and in Spanish children with DM1 [6].
Faecalibacterium prausnitzii, a butyrate-producing bacter-
ium, has been shown to have some anti-inflammatory
effects and has been found to be decreased in children
with diabetes-related autoantibodies [3].
Prebiotics are defined as selectively fermented ingredi-
ents that result in specific changes in the composition
and/or activity of the gastrointestinal microbiota, thus
conferring benefit(s) upon host health [7]. Prebiotics have
been shown to increase the abundance of both bifidobac-
teria and Faecalibacterium prausnitzii [8] and, therefore,
may help correct defects in the gut microbial environment
associated with DM1 development and progression.
Beyond reducing dysbiosis in the gut microbial envir-
onment, prebiotics have also been shown to improve
glucose tolerance via mechanisms that likely include
enhanced production and secretion of the incretin
glucagon-like peptide 1 (GLP-1) [9]. Indeed, prebiotics
improved hemoglobin A1c (HbA1c), postprandial gly-
cemic excursion and inflammatory markers in patients
with type 2 diabetes [9, 10]. To date however, there
have been no studies examining the effect of using
prebiotics to alter gut microbiota and intestinal per-
meability in children with DM1 and whether such
changes can improve glycemic control.
In addition to increased incretin production, prebi-
otics may improve glycemia through its action on
intestinal mucosal barrier function and gut micro-
biota [11–14]. Both animal and human studies have
linked gut microbiota to metabolic dysregulation.
Patients with diabetes have distinct gut microbiota in
comparison to healthy individuals [3, 4], with a
higher gram-negative to gram-positive bacterial ratio
and a lower abundance of bifidobacteria, an import-
ant microbial population with many health benefits
[1, 15, 16].
In animal studies, diabetes is also associated with
increased gut permeability, allowing bacterial lipopoly-
saccharides (LPS) from gram-negative bacteria to
translocate into the systemic circulation, causing meta-
bolic endotoxemia, triggering pro-inflammatory cytokine
secretion and insulin resistance [17–19]. Animal stud-
ies showed that prebiotic treatment dose-dependently
increases bifidobacteria [20], reduces gut permeability
and endotoxemia [21, 22] and improves glucose toler-
ance [23]. Indeed, bifidobacteria abundance negatively
correlates with serum LPS, fasting insulin and glucose
[21]. Prebiotics also enhance GLP-2 production, which
restores tight junction protein expression and reduces
gut permeability [18]. Hence, prebiotics may improve
glucose homeostasis by two separate mechanisms: (1)
up-regulating GLP-1 to improve beta-cell mass and
function, and (2) altering gut microbiota and perme-
ability to a less pro-inflammatory phenotype, improv-
ing insulin sensitivity. In humans, bacterial endotoxin
activity has been shown to be associated with insulin
resistance [24]. However, direct manipulation of gut
microbiota in humans and its impact on gut perme-
ability and glycemic control has not been studied, and
whether these mechanisms also operate in humans is
unknown.
Prebiotics are a potentially novel, inexpensive, low-
risk treatment addition for DM1 that may improve
glycemic control by changes in gut microbiota, gut
permeability and inflammation. This pilot study will
provide critical proof of concept data for future trials
looking at the efficacy of using prebiotics as an
adjunct in the management of DM1 to improve gly-
cemic control.
The primary objective of this study is to determine
the effect of a 12-week dietary intervention with
8 g/day of prebiotic intake compared to placebo on
glycemic control as measured by HbA1c in children
diagnosed with DM1 for at least one year. The sec-
ondary objective is to determine the gut microbiota
composition in children diagnosed with DM1 con-
suming prebiotic versus placebo. Further, we aim to
examine the differences in gut permeability, serum
inflammatory markers, glucagon-like peptide 1 (GLP-
1) and GLP-2 and C-peptide in children diagnosed
with DM1 consuming prebiotics versus placebo and
to assess for diabetes-related adverse reactions (i.e.
severe hypoglycemia and diabetic ketoacidosis) asso-
ciated with use of prebiotics in children with DM1.
Methods/design
Design
This pilot study is a single-centre, randomized, double-
blind, placebo-controlled trial of prebiotic treatment on
gut microbiota, intestinal permeability and glycemic
control in children aged 8 to 17 years who have had
DM1 for at least one year. A schematic of the study de-
sign is given in Fig. 1.
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Centre and patient selection
Patients will be recruited from the diabetes clinic at the
Alberta Children’s Hospital located in Calgary, Alberta,
Canada. This is a tertiary care hospital that provides
diabetes care to approximately 900 children with DM1.
The inclusion and exclusion criteria are outlined in
Table 1.
Patient recruitment
Patients will be approached during their regular dia-
betes clinic visits to participate in this study. Posters
and information pamphlets will be available so that
families can contact the research team if they are in-
terested in participating. Patients will be assessed for
eligibility and written informed consent, and where
appropriate, assent will be obtained for all study
participants.
Randomization
Participants will be randomized via computer-generated
numbers to intervention or placebo control in a 1:1 ra-
tio. The intervention and placebo groups will not be
matched (e.g. age, duration of T1DM, etc.). An inves-
tigator not involved in running the study will prepare
the randomization sequences and have the random
Fig. 1 CONSORT flow diagram
Table 1 Participant inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Age 8 years to 17 years (inclusive) • Any hemoglobin A1c greater than 10 % in the previous 6 months
• Diagnosed with type 1 diabetes for at least 12 months • Chronic medical condition that could affect gut microbiota (examples:
Crohn’s disease, cystic fibrosis, irritable bowel syndrome, etc.)
• Followed at the Alberta Children’s Hospital diabetes clinic
(Calgary, Alberta, Canada)
• Receiving medications or supplements that could affect gut microbiota
(examples: antibiotics, probiotics, prebiotics, laxatives, etc.)
• Parent or legal representative of the patient is willing to
give consent for the study and child assents
• Positive celiac disease screen
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allocation sequence in numbered envelopes in a se-
cure location that will be opened only once a partici-
pant has consented and enrolled in the study. The
participants, trial coordinator and research staff who
enroll the patients will remain blinded to the partici-
pants’ group assignment. Participants will be asked at
the end of the study to which group they believed
they were assigned.
Intervention
Participants will be randomized to receive either placebo
(maltodextrin 3.3 g orally/day; Agenamalt 20.222,
Agrana Starch, Konstanz, Germany) or prebiotic (oligo-
fructose-enriched inulin 8 g orally/day; Synergy1, Beneo,
Mannheim, Germany). Inulin and oligofructose are ap-
proved as food ingredients in Canada and have been
used previously in clinical trials [8, 25]. Both the pre-
biotic and placebo will be provided to participants in
powder form in identical foil pre-weighed packets.
Participants will be instructed to mix the packet
with 250 mL of water until dissolved and to drink it
15–20 minutes prior to their evening meal. For the
first 2 weeks, participants will be asked to only take
half of the dose in order to minimize gastrointestinal
side effects, and then they will take the full dose for
the remaining 10 weeks.
Participants will be asked to record any diabetes-related
or gastrointestinal adverse reactions, i.e. frequency of mild
hypoglycemia (symptoms of hypoglycemia with a blood
glucose less than 4 mmol/L and able to self-treat with
oral rapid-acting carbohydrate), severe hypoglycemia
(symptoms of hypoglycemia with a blood glucose less
than 4 mmol/L but requires assistance with treatment
due to decreased level of consciousness or has a seiz-
ure), diabetic ketoacidosis or flatulence. At the end of
the 12 weeks, participants will be asked to return any
remaining packets of placebo or prebiotic in order to
assess for compliance. Telephone contact from a
member of the research team will occur monthly to
encourage compliance and recording of adverse
reactions.
Data collection
Study visits will be coordinated with diabetes clinic
visits; the data to be collected are outlined in Table 2.
Demographic information will be collected at baseline.
Anthropometric measures and assessment of insulin reg-
imens, frequency of diabetic ketoacidosis (DKA) in pre-
vious 3 months, frequency of severe hypoglycemia in
previous 3 months and average number of mild
hypoglycemic episodes per week in the preceding
3 months will be assessed at baseline, 3 months and
6 months.
Glycemic control, inflammatory markers, GLP-1 and GLP-2
Blood will be collected at baseline, 3 months and
6 months for serum C-peptide, HbA1c, serum inflam-
matory markers (IL-6, IFN-gamma, TNF-alpha and IL-
10), GLP-1 and GLP-2. Serum will be sent to Calgary
Laboratory Services (Calgary, AB, Canada) for measure-
ment of HbA1c by turbidimetric inhibition immuno-
assay (Roche Integra 800 CTS, Basel, Switzerland) and
serum C-peptide by chemiluminescent assay (Siemens
Immulite 2000, Erlangen, Germany). Serum inflamma-
tory markers will be analysed by Milliplex Human Cyto-
kine Magnetic Bead Multiplex kits (Millipore, St.
Charles, MO, USA). GLP-1 and GLP-2 will be measured
with ELISA kits (Millipore, St. Charles, MO, USA).
Intestinal permeability
Intestinal permeability will be assessed at baseline,
3 months and 6 months. Participants will consume a
regular evening meal and then 3 hours later, prior to
bedtime, drink a solution containing lactulose (5 g),
mannitol (2 g) and 3-O-methylglucose (5 g) in 200 mL
of water (Biosource, Canada). All urine for the following
12 hours will be collected with 5 mL thymol in the stor-
age container for preservation, and stored frozen. High-
performance liquid chromatography (HPLC) will be used
to analyse urine samples for the lactulose, mannitol and
3-O-methylglucose content. Urine samples will be fil-
tered through a 0.4-μm filter and diluted as necessary.
Samples will be deionized and injected into an ion ex-
change column and eluted with NaOH at a flow rate of
0.4 mL/min with concentrations ranging from 400 to
600 mM. Peaks will be detected using pulse and amper-
ometric detection in a Dionex HPLC. The fraction of the
ingested dose recovered in the urine sample will be cal-
culated and compared between the two groups [26, 27].
Gut microbial profiling
Stool samples will be collected at baseline, 3 months and
6 months as previously described [14, 20]. Participants
will be provided with a Bristol stool chart and asked to
mark down the type of stool (type 1 to type 7). Partici-
pants will be provided a stool collection kit and will be
instructed on proper methods for stool collection. One
tablespoon of stool will be placed in a pre-labelled sterile
conical tube, placed in a biohazard bag and stored in the
home freezer (–20 °C). Participants will bring samples to
the laboratory up to 3 days from collection on ice, and
then the samples will be stored in the laboratory freezer
at –80 °C until analysed. Total bacterial DNA will be ex-
tracted from stool samples using the FastDNA Spin Kit
for Feces (MP Biomedicals, Lachine, QC, Canada)
followed by ethanol precipitation purification. DNA will
be quantified using Qubit dsDNA assay (Promega,
Madison, WI, USA) and diluted to 5 ng/μL
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concentration. Microbial composition will be determined
as per our previously published protocol [28] following
Illumina’s 16S rRNA amplicon sequencing protocol on
the MiSeq platform (Illumina, San Diego, CA, USA).
The V3 and V4 regions of the 16S rRNA gene will be
amplified using 2.5 μL (5 ng/μL) microbial DNA, 5 μL
(1 μM) of gene-specific primers and 12.5 μL 2x KAPA
HiFi Hotstart Ready Mix (KAPA Biosystems, Boston,
MA, USA). Following amplification, the PCR product
will be purified (Ampure XP beads, Beckman Coulter,
Mississauga, ON, Canada) and the amplicon size con-
firmed. Dual-indexed barcodes will be attached to ampli-
con targets in a second PCR stage. The final PCR
product will be purified (Ampure XP beads, Beckman
Coulter, Mississauga, ON, Canada) and quantified using
the Qubit dsDNA assay (Promega). Amplicon size will
be assessed using a D1000 TapeStation (Agilent Tech-
nologies) assay and samples normalized to 4 nM using
10 mM Tris pH 8.5. After pooling barcoded libraries,
samples will be denatured and diluted to a final concen-
tration of 4 pM, and a final product containing 10 %
PhiX will undergo dual-indexed paired 300 bp sequen-
cing on the MiSeq using Reagent kit v3 (Illumina).
Paired-end reads will be merged using PEAR (Paired-
End read merger) [29], and data analysis will be per-
formed using the Quantitative Insights into Microbial
Ecology (QIIME) pipeline version 1.9.1 [30]. Operational
taxonomic units (OTUs) will be picked using UCLUST
[31] with a 97 % sequence identity threshold followed by
taxonomy assignment using the latest Greengenes data-
base (http://greengenes.secondgenome.com). To evaluate
beta diversity, principal coordinate analysis (PCoA) on
weighted UniFrac distances will be performed on all
OTUs using QIIME. Alpha diversity will be measured by
calculating the Shannon index, Simpson index and
Chao1 metrics using QIIME [30]. A false discovery rate
Table 2 Study procedures and data collection
Ho et al. Trials  (2016) 17:347 Page 5 of 8
will be used to control for type 1 error. Given that 16S
rRNA sequencing generates relative abundance data, we
will also quantify the abundance of select microbial
groups (e.g. F. prausnitzii, Bifidobacterium spp., total
bacteria) with quantitative PCR according to our previous
work [14, 20] using the Bio-Rad iCycler (Bio-Rad Inc.,
Mississauga, ON) and group-specific primers.
Sample size
Internal pilot
The initial pilot study will aim to test the feasibility of a
fully powered studied in children with type 1 diabetes.
To test feasibility in this pilot study, we will enroll 15
subjects per arm. If we assume a drop-out rate of 20 %
(12 subjects completing the study in each arm), power of
80 %, and alpha of 0.05 and a standard deviation of 1.3
for HbA1c, then with the pilot study we would be able
to detect a mean difference in the absolute HbA1c of 1.5
between the placebo and prebiotic groups.
Full trial
For the full study, the sample size was calculated for a
two-sided t test comparing two independent samples.
Based on previous follow-up data from the Alberta Chil-
dren’s Hospital Diabetes Clinic, the mean score of HbA1C
at baseline in both groups will be estimated to be 8.4 with
a standard deviation of 1.3 for each group. A clinically sig-
nificant change in absolute HbA1c of 0.5 will be used, as
this threshold has been used in previous drug trials to
demonstrate effectiveness in diabetes. For a power of 80 %
and an alpha of 0.05, the number of subjects needed per
arm of the study is 107. If we assume a drop-out rate of
20 %, then approximately 135 subjects per arm of the
study will be required in a fully powered study.
Analysis
Analysis will be performed using SPSS 22.0 software
(IBM, New York, USA). Results will be considered statis-
tically significant if p ≤ 0.05. Baseline descriptive data
between the control and intervention group will be com-
pared using chi-square for categorical variables and t
tests for continuous variables. The primary outcome of
HbA1c will be expressed as mean HbA1c values with
standard deviations, and a two-sided t test will be used
to compare HbA1c between placebo and prebiotic
groups. Differences between the placebo and prebiotic
groups’ C-peptide, inflammatory markers (IL-6, IFN-
gamma, TNF-alpha, and IL-10), GLP-1, GLP-2 and in-
testinal permeability will be compared using a two-sided
t test. Adverse events will be presented as the proportion
of each event seen in each group (placebo and prebiotic).
An intent-to-treat analysis will be used with the last data
point carried forward for missing data. A secondary ana-
lysis will also be performed on a per-protocol basis with
all subjects who have completed the intervention and
are reported to be compliant with ≥80 % of the prebiotic
or placebo packets consumed.
Discussion
DM1 in children is a chronic disease with the current
mainstay of treatment being subcutaneous insulin ad-
ministration multiple times a day, frequent capillary
glucose monitoring and monitoring/counting carbohy-
drate intake at all meals and snacks. The management
regimen in DM1 is invasive and labor intensive and may
not always result in optimal glycemic control. Therefore,
the addition of a simple, oral supplement such as a pre-
biotic to improve glycemic control would be very benefi-
cial in this population.
Based on animal and human studies to date [9], we an-
ticipate that a change in gut microbiota, gut permeability
and inflammatory markers could occur over the course
of several weeks of prebiotic supplementation. Hence,
we anticipate that changes in these parameters will be
detectable at the 3-month follow-up. The change in
HbA1c will likely lag behind — as the life span of glyco-
sylated red blood cells is 3 months, any improvement in
glycemic control as a result of the 3-month prebiotic treat-
ment may not be fully reflected at the 3-month follow-up,
but may only become detectable at the 6-month follow-up.
We will reassess all these parameters at 6 months to deter-
mine the persistence of effects and whether continued
consumption of prebiotics is necessary to maintain the
changes in gut microbiota, gut permeability and inflamma-
tory markers observed.
Kellow et al. [9] published a systematic review on the
metabolic benefits of prebiotics in human randomized
controlled trials. Meta-analysis indicated a statistically
significant effect of prebiotics on reduction in post-
prandial glucose and post-prandial insulin levels. Con-
flicting results were seen in studies looking at fasting
glucose, fasting insulin and HbA1c. No pediatric studies
or populations with DM1 were identified for inclusion in
this systematic review.
Murri et al. showed that children with established
DM1 have different gut microbiota from children with-
out T1DM [6]. In addition to changes in the gut micro-
biota, altered gut permeability may also contribute to
the pathogenesis of type 1 diabetes, as increased ‘gut
leakiness’ has been shown in animal models preceding
the development of diabetes [26]. It is hypothesized that
the increased gut permeability allowed continued expos-
ure to antigens that contribute to aspects of the immune
dysregulation observed in DM1 [1]. Importantly, prebi-
otics have been shown to reduce gut permeability
through a mechanism that involves GLP-2, a gut trophic
factor [18]. In this current study, we aim to determine if
treatment with prebiotics can decrease gut permeability,
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which will decrease endotoxemia and reduce insulin
resistance. Improved insulin resistance may lead to im-
proved glycemic control. In future studies, the role of
prebiotics in altering disease progression in pre-diabetes
will be examined.
This study will provide valuable information on
whether the consumption of a prebiotic will alter gut
microbiota and intestinal permeability in children with
type 1 diabetes. This could potentially lead to improved
glycemic control and adjunctive therapy that is inexpen-
sive and easy to administer.
Trial status
The protocol has been approved by the Conjoint Health
Research Ethics Board, University of Calgary (Calgary,
Alberta, Canada) 10 June 2015 and has been registered
at ClinicalTrials.gov on 10 March 2015 (NCT02442544).
Recruitment has just commenced at Alberta Children’s
Hospital.
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